ePrivacy and GPDR Cookie Consent by TermsFeed Generator

FULVESTRANT EVER PHARMA

250MG INJ SOL ISP 2X(2X5ML)

Maximum ex-factory price/Ex-factory price ? 18265,54 CZK
Legal basis of maximum ex-factory price/ex-factory price ? Maximum ex-factory price set by the law.

Informace o základní úhradě

Core reimbursement from health insurance ? 15809,48 CZK
Maximum reimbursement from health insurance ? 20981,25 CZK
Legal basis of reimbursement from health insurance ? Reimbursement set by the law.
Indication restriction of reimbursement ? Fulvestrant je hrazen v léčbě hormonálně dependentního (ER pozitivního) lokálně pokročilého nebo metastatického karcinomu prsu u postmenopauzálních žen: 1) po vyčerpání předchozí léčby tamoxifenem a inhibitory aromatázy (tj. ve 3. linii léčby) při relapsu onemocnění v průběhu nebo po adjuvantní antiestrogenové terapii nebo progresi onemocnění při léčbě antiestrogeny. 2) které nebyly dříve léčeny endokrinní léčbou, pokud jejich stav výkonnosti odpovídá ECOG 0-1 a pokud nejsou onemocněním postiženy viscerální orgány. Pro oba body platí, že fulvestrant je hrazen do progrese onemocnění či do doby, kdy pacientka léčbu přestane snášet.
Prescribing doctor's specialisation ? Clinical oncology, pediatric hematology and oncology, radiation onkology and gynecologic oncology
Reporting limit ? AE: Unless it is advisable to transfer the prescription of the product to another doctor under paragraph 2 in light of the effect and safety of the product, the "E" symbol will mark the product in the decision.
The decision shall allocate the "A" symbol to products administered, in light of its nature, by a doctor in outpatient care. This product shall be charged to the health insurer along with the relevant intervention as a separately charged product. If advisable given the effect and safety of the product or if in the public interest, reporting of "A" products shall be restricted to doctors with specialist capacity, with the specialist field stated in the decision.
Rough price for the final consumer ? 21437,74 CZK
Rough payment for the final consumer (for 1 prescribed package dispensed) ? 456.49 CZK
Eligible extra payment ?
Eligible extra payment for individuals aged 65 and older ?
Medicinal products reimbursed from health insurance contain the amount of the maximum manufacturer´s price or the producer´s notified price for products which are not subjected to the regulation of the maximum manufacturer´s price, the amount of reimbursement from health insurance and the estimated price for the end consumer (pharmacy price).

Back to list